What is Complement 1?
Founded in 2024 and based in the United States, Complement 1 operates within the healthcare industry, focusing on a clinically validated, AI-driven lifestyle modification platform. This platform is specifically designed for cancer patients, survivors, and individuals at high risk. The company's core offering is a personalized daily coaching program, delivered by certified CoActive Coaches, integrated with evidence-based interventions in nutrition, physical activity, and mind-body practices. Clinical trials have validated the platform's efficacy, demonstrating substantial improvements in patient outcomes, including the reduction of treatment side effects and an overall enhancement in quality of life.
How much funding has Complement 1 raised?
Complement 1 has raised a total of $16M across 1 funding round:
Seed
$16M
Seed (2025): $16M with participation from Owl Ventures and Blume Ventures
Key Investors in Complement 1
Owl Ventures
Owl Ventures is a global leader in education technology investing, focusing on innovative solutions that enhance learning experiences. The company supports a diverse range of edtech companies, including those providing tools for personalized tutoring, virtual classrooms, and workforce upskilling. With a deep understanding of the K-12 space and a strong network, Owl Ventures plays a crucial role in scaling its portfolio companies globally. Their commitment to democratizing access to quality education drives their investment philosophy and partnership approach.
Blume Ventures
Blume Ventures is an India focused early stage investment firm that backs founders from seed through scale up. With local insight and hands on support, it partners with teams building enduring technology led businesses across consumer, enterprise and deep tech, helping them raise capital, sharpen strategy and grow responsibly.
What's next for Complement 1?
The recent major strategic investment signals a pivotal growth phase for Complement 1, likely enabling the company to scale its operations, expand its market reach, and further develop its AI-driven platform. This capital infusion is expected to accelerate the company's mission to provide accessible and effective lifestyle modification support for individuals navigating cancer treatment and recovery. The company's focus on personalized coaching and evidence-based interventions positions it for significant impact within the evolving landscape of oncology care and digital therapeutics.
See full Complement 1 company page
